Wall Street analysts expect vTv Therapeutics (NASDAQ:VTVT) to report $3.14 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for vTv Therapeutics’ earnings, with the lowest sales estimate coming in at $100,000.00 and the highest estimate coming in at $8.00 million. vTv Therapeutics posted sales of $30,000.00 in the same quarter last year, which would indicate a positive year-over-year growth rate of 10,366.7%. The company is scheduled to announce its next quarterly earnings report on Wednesday, May 2nd.
According to Zacks, analysts expect that vTv Therapeutics will report full-year sales of $10.88 million for the current year, with estimates ranging from $200,000.00 to $30.00 million. For the next financial year, analysts anticipate that the company will post sales of $13.40 million per share, with estimates ranging from $200,000.00 to $30.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that cover vTv Therapeutics.
vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.03). The business had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.10 million.
VTVT stock traded down $0.02 during midday trading on Friday, reaching $2.09. 3,407,735 shares of the company were exchanged, compared to its average volume of 3,335,958. The company has a current ratio of 0.76, a quick ratio of 0.76 and a debt-to-equity ratio of -0.10. vTv Therapeutics has a 1-year low of $0.65 and a 1-year high of $8.40. The stock has a market cap of $69.23, a P/E ratio of -1.25 and a beta of 1.74.
Several institutional investors have recently made changes to their positions in the company. State Street Corp increased its holdings in shares of vTv Therapeutics by 2.1% in the 2nd quarter. State Street Corp now owns 98,016 shares of the biotechnology company’s stock valued at $486,000 after acquiring an additional 1,976 shares during the period. Creative Planning acquired a new position in shares of vTv Therapeutics in the 4th quarter valued at $114,000. Millennium Management LLC acquired a new position in shares of vTv Therapeutics in the 4th quarter valued at $377,000. JPMorgan Chase & Co. acquired a new position in shares of vTv Therapeutics in the 3rd quarter valued at $481,000. Finally, Royce & Associates LP acquired a new position in shares of vTv Therapeutics in the 4th quarter valued at $1,352,000. 11.20% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This piece was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3377923/vtv-therapeutics-vtvt-expected-to-post-quarterly-sales-of-3-14-million.html.
About vTv Therapeutics
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.